These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 21190975)

  • 1. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
    Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
    J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.
    Amar L; Baudin E; Burnichon N; Peyrard S; Silvera S; Bertherat J; Bertagna X; Schlumberger M; Jeunemaitre X; Gimenez-Roqueplo AP; Plouin PF
    J Clin Endocrinol Metab; 2007 Oct; 92(10):3822-8. PubMed ID: 17652212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
    Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.
    Oh DY; Kim TW; Park YS; Shin SJ; Shin SH; Song EK; Lee HJ; Lee KW; Bang YJ
    Cancer; 2012 Dec; 118(24):6162-70. PubMed ID: 22736481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pheochromocytoma and sympathetic paragangliomas].
    Zollinger R; Hedinger C
    Schweiz Med Wochenschr; 1983 Jul; 113(30):1057-65. PubMed ID: 6623024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
    Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
    Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes.
    Ezzat Abdel-Aziz T; Prete F; Conway G; Gaze M; Bomanji J; Bouloux P; Khoo B; Caplin M; Mushtaq I; Smart J; Kurzawinski TR
    J Surg Oncol; 2015 Oct; 112(5):486-91. PubMed ID: 26337393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up.
    Stenman A; Zedenius J; Juhlin CC
    Surgery; 2019 Nov; 166(5):901-906. PubMed ID: 31239074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma.
    Hescot S; Leboulleux S; Amar L; Vezzosi D; Borget I; Bournaud-Salinas C; de la Fouchardiere C; Libé R; Do Cao C; Niccoli P; Tabarin A; Raingeard I; Chougnet C; Giraud S; Gimenez-Roqueplo AP; Young J; Borson-Chazot F; Bertherat J; Wemeau JL; Bertagna X; Plouin PF; Schlumberger M; Baudin E;
    J Clin Endocrinol Metab; 2013 Oct; 98(10):4006-12. PubMed ID: 23884775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the insulin-like growth factor 1 receptor (IGF-1R) is associated with malignancy in familial pheochromocytomas and paragangliomas.
    Fernandez MC; Martin A; Venara M; Calcagno Mde L; Sansó G; Quintana S; Chemes HE; Barontini M; Pennisi PA
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):623-30. PubMed ID: 23506534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.
    De Filpo G; Cantini G; Rastrelli G; Vannini G; Ercolino T; Luconi M; Mannelli M; Maggi M; Canu L
    J Endocrinol Invest; 2022 Jan; 45(1):149-157. PubMed ID: 34227051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
    Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
    Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
    Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
    Guo Z; Lloyd RV
    Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma.
    Roman-Gonzalez A; Zhou S; Ayala-Ramirez M; Shen C; Waguespack SG; Habra MA; Karam JA; Perrier N; Wood CG; Jimenez C
    Ann Surg; 2018 Jul; 268(1):172-178. PubMed ID: 28257320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histopathology, cytology and cytochemistry of pheochromocytomas and paragangliomas including chemodectomas.
    Capella C; Riva C; Cornaggia M; Chiaravalli AM; Frigerio B; Solcia E
    Pathol Res Pract; 1988 Apr; 183(2):176-87. PubMed ID: 2838831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
    Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
    Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Glycomic Profiling of Pheochromocytomas and Paragangliomas Separates Metastatic and Nonmetastatic Disease.
    Leijon H; Kaprio T; Heiskanen A; Satomaa T; Hiltunen JO; Miettinen MM; Arola J; Haglund C
    J Clin Endocrinol Metab; 2017 Nov; 102(11):3990-4000. PubMed ID: 28938401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
    Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas.
    Job S; Georges A; Burnichon N; Buffet A; Amar L; Bertherat J; Bouatia-Naji N; de Reyniès A; Drui D; Lussey-Lepoutre C; Favier J; Gimenez-Roqueplo AP; Castro-Vega LJ
    J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31678991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.